New Stock News | Bolexikang submitted an application to the Hong Kong Stock Exchange, with its core products being BB-1701, BB-1705, and other ADCs in the clinical stage

According to the Hong Kong Stock Exchange's disclosure on June 29, BlissBio Inc. (abbreviated as BaiLiSiKang) has submitted a listing application to the main board of the Hong Kong Stock Exchange, with Goldman Sachs, Huatai International, and Jianyin International as joint sponsors. According to the prospectus, BaiLiSiKang is a clinical-stage biopharmaceutical company dedicated to developing next-generation antibody-drug conjugates (ADCs) to address significant unmet needs in current cancer treatments. The company strategically designs and advances an ADC pipeline consisting of four clinical-stage candidates. The company's core product, BB-1701 (core product), is a human epidermal growth factor receptor 2 (HER2) targeted Aitibulin ADC candidate, primarily aimed at breast cancer (BC), non-small cell lung cancer (NSCLC), and potentially other HER2-expressing cancers. In addition to the core product, the company has three other ADCs in clinical stages: BB-1705 (an epidermal growth factor receptor (EGFR) ADC), BB-1712 (an anti-B7 homolog 3 (B7-H3) ADC), and BB-1709 (a cluster of differentiation 73 (CD73) ADC), which have potential across a wide range of indications. The company holds complete global rights to all pipeline assets. BB-1701 is the leading HER2 ADC candidate globally for patients previously treated with TOP1-i ADC. Aitibulin, as a class of cancer therapies approved in over 70 countries, is utilized in BB-1701 as the ADC payload, leveraging Aitibulin's multifaceted mechanism of action, differentiated resistance mechanisms, and its clinically validated efficacy and safety for cancer treatment in over 70 countries. Based on ongoing Phase II studies in the United States, Europe, Japan, and China, BB-1701 has shown encouraging efficacy and controllable safety, particularly with only three cases of interstitial lung disease (ILD) among 260 patients (two cases of Grade 1 and one case of Grade 2), showing improvement over Herceptin®. The company's internal chemistry, manufacturing, and control (CMC) development and manufacturing capabilities are essential for providing high-quality, efficient, and cost-effective solutions in antibody development, conjugation processes, formulation, and ADC construction. By adhering to the principle of "process equals product," the company establishes robust production processes and ensures strict quality control and assurance throughout the development cycle. These capabilities enable the company to advance a project from a preclinical candidate to Investigational New Drug (IND) status in 14 months, significantly faster than the industry average of 18 months, according to Frost & Sullivan data. Multiple IND approvals granted by global regulatory agencies in the United States, China, the European Union, and Japan demonstrate the capabilities of the company's CMC platform In terms of finance, in the fiscal year 2023 and 2024, Baile Sikang achieved revenues of approximately 180 million yuan and 22.591 million yuan respectively; during the same period, the losses were approximately 206 million yuan and 557 million yuan.